Clinical trial · no report yet · Phase 2
NeoSTAR
Sacituzumab Govitecan In TNBC
- NCT04230109 ↗
- Recruiting
- Massachusetts General Hospital
- 82 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 33 | |
| Podcasts | 27 | |
| YouTube | 21 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Invasive Breast Cancer; Triple Negative Breast Cancer; ER-Negative Breast Cancer; PR-Negative Breast Cancer; HER2-negative Breast Cancer
- Interventions
- Sacituzumab Govitecan; Pembrolizumab
- Arms
- Sacituzumab Govitecan (monotherapy cohort) · Experimental
- Sacituzumab Govitecan and Pembrolizumab (combination cohort) · Experimental
- Enrollment
- 239 (estimated)
- Primary outcomes
- Pathological complete response(pCR) rate with sacituzumab govitecan
- Sponsor
- Massachusetts General Hospital with Gilead Sciences
- Start
- Jul 14, 2020
- Primary completion
- Oct 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04230109 · updated Jul 17, 2026
Publications
linked from the registry- Spring LM, Tolaney SM, Fell G, Bossuyt V, Abelman RO, Wu B, Maheswaran S, Trippa L, Comander A, Mulvey T, McLaughlin S, Ryan P, Ryan L, Abraham E, Rosenstock A, Garrido-Castro AC, Lynce F, Moy B, Isakoff SJ, Tung N, Mittendorf EA, Ellisen LW, Bardia A. Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. Ann Oncol. 2024 Mar;35(3):293-301. doi: 10.1016/j.annonc.2023.11.018. Epub 2023 Dec 12. PubMed 38092228